Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is NeuroOne Medical Technologies FCF Margin %?
NeuroOne Medical TechnologiesNMTC -4.00%21 FCF Margin % is -73.47% as of Mar. 2026. GuruFocus rates NMTC with a GF Score™ of 21/100. The stock has 4 warning signs investors should review. Among 814 Medical Devices & Instruments companies, NeuroOne Medical Technologies ranks worse than 83.42% on this metric.
The historical rank and industry rank for NeuroOne Medical Technologies's FCF Margin % or its related term are showing as below:
NMTC'
s FCF Margin % Range Over the Past 10 Years
Min: -4870.79 Med: -679.87 Max: -32.08
Current: -82.35
During the past 13 years, the highest FCF Margin % of NeuroOne Medical Technologies was -32.08%. The lowest was -4870.79%. And the median was -679.87%.
NMTC's FCF Margin % is ranked worse than 83.42% of 814
companies
in the Medical Devices & Instruments industry
Industry Median: -0.815
vs NMTC: -82.35
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, NeuroOne Medical Technologies's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeuroOne Medical Technologies FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NeuroOne Medical Technologies's FCF Margin % distribution charts can be found below:
* The bar in red indicates where NeuroOne Medical Technologies's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeuroOne Medical Technologies (NMTC) has a FCF Margin % of -73.47% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on NeuroOne Medical Technologies and its competitors. According to the industry distribution chart, NeuroOne Medical Technologies ranks #679 out of 814 companies in the Medical Devices & Instruments industry, placing it in the top 83.4%.
Is NeuroOne Medical Technologies' FCF Margin % too high?
NeuroOne Medical Technologies' current FCF Margin % is -73.47%. Based on the distribution chart, NeuroOne Medical Technologies ranks #679 out of 814 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, NeuroOne Medical Technologies has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does NeuroOne Medical Technologies' FCF Margin % compare to CSDX and IRIX?
According to the Medical Devices & Instruments industry distribution chart, NeuroOne Medical Technologies ranks #679 out of 814 companies for FCF Margin %. This places NeuroOne Medical Technologies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on NeuroOne Medical Technologies and its competitors. NeuroOne Medical Technologies's current FCF Margin % is -73.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroOne Medical Technologies stock overvalued right now?
NeuroOne Medical Technologies (NMTC) has a current FCF Margin % of -73.47%. The current FCF Margin % is -73.47%. NeuroOne Medical Technologies' overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For NeuroOne Medical Technologies (NMTC), the current FCF Margin % is -73.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
21GF Score
Get the complete analysis for NMTC
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NMTC has been successfully added to your 
